Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
C2orf49 divergent transcript (C2orf49-DT) refers to a non-coding RNA transcript expressed in a divergent orientation from the genomic locus of the protein-coding gene C2orf49 (chromosome 2 open reading frame 49). Divergent transcripts are typically long non-coding RNAs (lncRNAs) that are generated by divergent transcription, a process in which promoters produce RNAs in both directions. While C2orf49 itself is a protein-coding gene with predicted roles in tRNA splicing and may participate in RNA processing complexes, the "divergent transcript" form (C2orf49-DT) does not encode a protein and lacks characterized biological function, molecular interactions, or disease associations. There is no evidence to date that C2orf49-DT acts as a therapeutic target, and it is not recognized as an established receptor, enzyme, transporter, or other therapeutic class. The entry "C2orf49 divergent transcript" is correctly labeled as a noncoding transcript but is not a validated therapeutic target. Most so-named "divergent transcripts" related to open reading frames (e.g., C2orfxx-DT) are catalogued in gene databases for annotation purposes, not for any known functional or druggable role. If your intent is to target C2orf49-DT therapeutically or include it in structured target lists, it should be excluded as there is insufficient evidence for biological or pharmacological relevance as a target. If you are seeking information on the protein-coding gene, use "Chromosome 2 open reading frame 49 (C2orf49)" instead, as this has defined molecular features and potential links to pathway biology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on C2orf49 divergent transcript (C2orf49-DT).